Is Moelis Australia Ltd the next Macquarie Group Ltd?

Could this recent IPO, Moelis Australia Ltd (ASX: MOE) grow into a billion-dollar investment bank?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investment bank Moelis Australia Ltd (ASX: MOE) has seen its share price hit a 52-week high of $3.95 today, a 68% jump so far since listing in April 2017 at an IPO price of $2.35 per share.

According to the company's prospectus, Moelis has grown from a small boutique financial advisory business to a financial services group active in two core segments: Corporate Advisory & Equities and Asset Management. It also has a strategic alliance with the US-listed investment bank, Moelis & Company, and Moelis & Co has retained a 40% holding in Moelis Australia.

Macquarie Group Ltd (ASX: MQG) is obviously much larger and has more business operations, but Moelis could grow into Australia's second-largest investment bank behind Macquarie.

While still in its infancy, Moelis generated $62 million of revenue in the 2016 financial year (FY16) and pro forma earnings before interest and tax (EBIT) of $18.8 million.

In the calendar year 2016 (CY16), Moelis generated $13.9 million in net profit and is forecasting $16.8 million in CY17.

At the IPO issue price, shares were trading at an adjusted P/E of 14.6x, with an annualised dividend yield of between 2.2% and 3.6%. That may not appear attractive, especially considering the 68% increase in the share price since the IPO, but Moelis should be considered a long-term investment i.e. at least three to five years. Of the ~$60 million raised in the IPO, roughly $44 million will be used by Moelis to grow the company, according to the prospectus.

Foolish takeaway

While the current price might be high, Moelis might be one financial stock to watch closely – particularly when it reports its half-year in August 2017.

Motley Fool writer/analyst Mike King doesn't own shares in any companies mentioned. You can follow Mike on Twitter @TMFKinga The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »